Loading...
Biocept, Inc.
BIOC•NASDAQ
Healthcare
Medical - Diagnostics & Research
$0.43
$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $5.59M in Q3 2022 to $589000.00 in Q2 2023. Gross profit remained healthy with margins at -333% in Q2 2023 compared to -3% in Q3 2022. Operating income hit -$6.11M last quarter, sustaining a consistent -1038% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.65M. Net income rose to -$3.63M, while earnings per share reached -$3.50. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan